Key result
Lower serum albumin linked to ~77% higher bleeding risk per 1 g/dL decrease in VTE.
Why the study?
The association between serum albumin levels and bleeding events in patients with venous thromboembolism treated with anticoagulants was unclear.
Are lower serum albumin levels associated with an increased risk of bleeding events in patients with venous thromboembolism treated with anticoagulants?
Cohort (n=732)
Yes
Are lower serum albumin levels associated with an increased risk of bleeding events in patients with venous thromboembolism treated with anticoagulants?
Decreased serum albumin levels serve as an independent risk marker for 180-day bleeding events in VTE patients on anticoagulation, especially among those with active cancer.
Answers are grounded in this paper and cite their sources.
Low albumin was associated with higher 180-day bleeding risk in anticoagulated VTE patients, especially with cancer; hypothesis-generating and should not yet change practice.
BACKGROUND: Association between serum albumin levels and bleeding events in patients with venous thromboembolism was unclear. METHODS: In this Japanese multi-center registry, we enrolled 993 consecutive patients diagnosed with acute venous thromboembolism and treated with anticoagulants between 2015 and 2024, where 732 patients were finally analysed. The primary outcome was 180-day bleeding events, defined as moderate or severe bleeding according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries criteria. The effect of serum albumin level on the outcome was determined using a multivariate Cox proportional hazard regression model adjusted for conventional bleeding risk scoring systems. RESULTS: The mean age was 68.6 ± 14.5 years, and 37.2% were men. In total, 38.4% had concomitant active cancer, 6% had a previous history of venous thromboembolism, and 90% were treated with direct oral anticoagulants. The primary outcome occurred in 36 patients (5%), and serum albumin level was significantly lower in the event group than in the event-free group (2.9 ± 0.7 g/dL versus. 3.2 ± 0.7 g/dL, P = 0.014). In multivariate Cox proportional risk analysis, serum albumin level was independently associated with the outcome (adjusted hazard ratio 1.77, per 1 g/dL decrease; 95% confidence interval, 1.12-2.75; P = 0.013). This was consistent in patients with active cancer (adjusted hazard ratio 2.15, per 1 g/dL decrease; 95% confidence interval, 1.29-3.57; P = 0.003), but not in patients without it. CONCLUSIONS: Decreased serum albumin levels were associated with 180-day bleeding events in patients with venous thromboembolism treated with anticoagulants, especially in those with concomitant active cancer.
No takes yet. Share an insight, caveat, or question.
Yoshioka et al. (2026) conducted a cohort in Acute venous thromboembolism (n=732). Decreased serum albumin level was evaluated on 180-day bleeding events (moderate or severe bleeding according to GUSTO criteria) (adjusted HR 1.77, 95% CI 1.12-2.75, p=0.013). Decreased serum albumin was associated with 180-day bleeding in patients with venous thromboembolism on anticoagulants.
Synapse has enriched 10 related papers. Consider them for comparative context: